Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03576651
Other study ID # JHL-CLIN-1149-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 24, 2018
Est. completion date December 13, 2019

Study information

Verified date January 2020
Source JHL Biotech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States (US) in Healthy Male Volunteers


Recruitment information / eligibility

Status Completed
Enrollment 154
Est. completion date December 13, 2019
Est. primary completion date September 17, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 21 Years to 55 Years
Eligibility Inclusion Criteria:

1. Healthy male volunteers,

2. Age range of 21-55 years (inclusive).

3. BMI range of 18.0-30.0 kg/m2 (inclusive) and a total body weight >50 kg.

4. Medically healthy subjects with normal organ functions and laboratory values

5. Subjects must be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing.

6. All intermittent medications including over the counter, herbal and nutriceuticals, must be stopped at least 14 days prior to admission to the clinical research center.

7. Ability and willingness to abstain from alcohol 48hrs prior to admission to the clinical research center, and throughout the dosing and evaluation period.

8. No significant medical history per the PI judgment.

9. ECGs (via 12 lead) showing normalized cumulative sum (NCS) findings per PI judgment

10. Ability to provide informed consent for the study.

Exclusion Criteria:

1. Previous treatment with an anti-vascular endothelial growth factor (VEGF) antibody or any other antibody or protein targeting the VEGF receptor or treatment with an immunobiological drug during the last three months.

2. Previous history of cancer other than adequately treated basal cell or squamous cell carcinoma of the skin.

3. Received blood transfusions and blood donation within 3 months before screening date.

4. Resting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg.

5. Any other severe physical incapacity.

6. Positive serological test for hepatitis B surface antigen or positive antibody for hepatitis C virus or positive antibody for human immunodeficiency virus (type 1 and 2).

7. Tuberculosis (TB) or an acute systemic infection; demonstrated by positive QuantiFERON-TB and/or Chest radiograph conducted up to 3 months prior or during the screening visit.

8. Major surgery planned for the study duration or cases with major surgery in the past 28 days before screening.

9. History of relevant drug and/or food related allergies.

10. History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients.

11. History of alcohol and or drug abuse/addiction.

12. Positive alcohol breath test and drug screen for opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines.

13. Strenuous exercise 96 hrs prior to admission to the clinical research center.

14. Any significant or acute illness within 30 days prior to the expected first dose of study drug.

15. Unsuitable veins for infusion and/or venepuncture.

16. History of bleeding disorders, thromboembolic conditions, gastrointestinal perforations or any fistulae, orthostatic hypotension, fainting spells, blackouts for any reasons; as well as presence of a non-healing wound or fracture.

17. Participation in another clinical study where the investigational drug was received within < 5 x half-lives of the drug (120 days prior to screening).

18. Any condition or displayed behaviour that the investigator in their best clinical judgement believes could be detrimental the subject's participation in the study or result in unfavourable outcomes for the subject or study (eg. Clear signs that the patient is withholding information on their substance use/abuse status).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
JHL1149
Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
Bevacizumab
Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
Bevacizumab
Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion

Locations

Country Name City State
Bulgaria MHAT Lyulin EAD Sofia

Sponsors (1)

Lead Sponsor Collaborator
JHL Biotech, Inc.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC0-inf area under the concentration-time curve from time zero to infinity (AUC0-inf) up to 71 days
Secondary AUClast Area under the serum concentration-time curve from time 0 to last quantifiable concentration (AUClast). up to 71 days
Secondary Cmax Maximum serum concentration just prior to end of infusion (Cmax) up to 71 days
See also
  Status Clinical Trial Phase
Completed NCT05621447 - A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects Phase 1
Completed NCT02901366 - Mass Balance Study of FYU-981 Phase 2
Not yet recruiting NCT01928563 - Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine Phase 1
Completed NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects Phase 1
Completed NCT04512872 - A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects Phase 1
Active, not recruiting NCT06111196 - Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Phase 1
Completed NCT03317652 - Effect of Sodium Nitroprusside on Cerebral Blood Flow N/A
Completed NCT04655872 - Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects Phase 1
Active, not recruiting NCT02609711 - Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects Phase 1
Withdrawn NCT02560363 - A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects Phase 1
Completed NCT01261260 - Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers Phase 1
Completed NCT05072028 - Mass Balance and Biotransformation Study of [14C]DBPR108 in Human Phase 1
Completed NCT05446233 - ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects Phase 1
Completed NCT05275010 - A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System Phase 1
Completed NCT04839744 - A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects Phase 1
Completed NCT05792917 - Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers Phase 1
Completed NCT04825431 - Mass Balance Study of [14C] TAS-205 in Healthy Volunteers Phase 1
Completed NCT01819779 - Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60) Phase 1
Completed NCT05126784 - AVT03 With Prolia in Healthy Male Subjects Phase 1
Completed NCT04850638 - Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) Phase 1